Q-omics provides the consensus-scored IFITM3P6 profile across patient tissues and cancer cell-line models. IFITM3P6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IFITM3P6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, IFITM3P6 RNA expression shows 14,951 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where IFITM3P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFITM3P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFITM3P6 survival associations across molecular data types. IFITM3P6 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFITM3P6 RNA expression–survival associations across cancer types. High IFITM3P6 expression shows unfavorable associations in KIRC, but favorable associations in SKCM, HNSC, LUAD, CESC and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IFITM3P6 RNA expression.
This table summarizes IFITM3P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IFITM3P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFITM3P6 shows lower tumor expression in LUSC, UCEC and LUAD and higher tumor expression in KIRC, HNSC and CHOL. The KIRC box plot shows higher IFITM3P6 RNA expression in tumor versus normal tissue (log2 FC = +1.048, t-test p < 0.001).
This table shows molecular features associated with IFITM3P6 in patient tissues and cancer cell lines. In patient samples, IFITM3P6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
